From 2008 to 2017, the review analyzes and contrasts seven main US and foreign allergic rhinitis recommendations. Despite the fact that there are several treatment choices for allergic rhinitis, patients frequently complain of a lack of therapeutic control and a worse quality of life. Guidelines aimed at improving allergic rhinitis care have evolved into evidence-based, systematic reviews, with less dependence on expert agreement that characterizes more conventional guidelines. The first Grading of Recommendations Assessment, Development, and Evaluation-based guideline for seasonal allergic rhinitis created in the United States was released in 2017.
When examining the allergic rhinitis recommendations using the rigorous Grading of Recommendations Assessment, Development, and Evaluation process, various groups of expert writers will reach different judgments about the quality of the evidence and the strength of the suggestion. Factors that could contribute to these disparities include a lack of objective primary outcome measures in allergic rhinitis, a poorly defined Minimal Clinically Important Difference, a failure to include all interested parties in guideline development, such as patients, and the expert panel’s inherent subjectivity.
